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HIV scoring showed a signiﬁcant relationship with scoring
assessed through MOS-HIV (R = -0.71; P < 0.01), and through
general health status (p < 0.01 ). MINI-HIV scoring showed a
signiﬁcant relationship with CD4 (p < 0.01), viral load and
symptoms (p < 0.001). Regarding responsiveness to change, a
high effect size in MINI-HIV was observed between those
patients whose general health status had improved during the
follow up visits (ES = 0.694 IC 95% 0.134–1.254). The internal
consistency of the questionnaire was assessed through the a
Cronbach (a = 0.93). The ICC (test—retest reliability) was 0.86.
CONCLUSIONS: The MINI-HIV has good psychometric prop-
erties and correlated with clinical markers of the disease.
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OBJECTIVES: This study aimed to assess the cross cultural
validity and reliability of Health Utility Index (HUI3) in UK HIV
population. METHODS: The study was approved by local
research ethics committee. All adult patients receiving HIV care
in Cardiff were approached in the outpatient clinic and recruited
into the study after giving written informed consent. Participants
were required to complete the HUI3. Variables analyzed include
QOL score, CD4+ category, HIV stage, antiretroviral (ARV)
usage and viral load using Spearman’s rank test, Kruskal-Wallis
and Mann-Whitney U test. RESULTS: In total, 103 (98%) of
participants completed the questionnaire. The average age of the
participant was 40.8 years (±10.7 SD) and 81 were male. HUI3’s
was found to be reliable in most attributes (Cronbach’s alpha
0.68), except in vision, hearing and ambulation. Four attributes
(ambulation, emotion, cognition and pain) correlated signiﬁ-
cantly with QOL score (p < 0.002) after controlling for anti-
retroviral use, clinical, and CD4+ categories. Findings also
revealed no signiﬁcant difference and correlation between QOL
score and CD4+ count, viral load count and HIV clinical cate-
gories. There appears to be a stronger correlation (r = -0.19) and
mean difference (P = 0.08) between QOL score and antiretrovi-
ral use but this did not reach statistical signiﬁcance. An inter-
esting pattern was observed whereby asymptomatic patients and
those not using antiretroviral (ARV) therapy had a lower QOL
score than AIDS patients. Class of ARV also appeared to affect
QOL score but was not signiﬁcant statistically (P = 0.2). CON-
CLUSION: The ﬁndings of this study support validity and reli-
ability of HUI3 in UK HIV population and therefore could be
used with conﬁdence in comparative study of HIV treatment.
The results also suggest beneﬁt of ARV use in improving patient
QOL and also the different effect of ARV regimen had on the
score; however this requires further investigation in a controlled
study.
PIN22
COST-UTILITY ANALYSIS OF A HYPOTHETICAL
VACCINATION PROGRAM AMONG THE CURRENTLY
TARGETED POPULATION IN THE NETHERLANDS IN CASE OF
AN INFLUENZA PANDEMIC
Meijboom M1, Buskens E1, Li-McLeod J2
1PharMerit, Rotterdam,The Netherlands; 2Baxter BioScience, Westlake
Village, CA, USA
OBJECTIVES: A modeling study was conducted to assess the
balance between costs and effects of a hypothetical inﬂuenza vac-
cination programme in case of an inﬂuenza pandemic in The
Netherlands. METHODS: An existing decision model was
expanded to comprise the entire population at risk and pandemic
attack rate. Dutch estimates regarding costs, frequency of GP
visits, hospitalization and mortality associated with inﬂuenza
and inﬂuenza related complications were used. The impact in
terms of (dis-)utility of inﬂuenza and the various inﬂuenza
related complications were retrieved and added. A societal per-
spective was used to account for direct medical costs and costs
associated with sick leave. Monte-Carlo simulation was used to
conduct multivariable sensitivity analyses. RESULTS: In the
absence of vaccination the model predicted 517,567 GP visits,
41,766 hospitalizations and 72,513 deaths in case of a pandemic.
Vaccination of the population at risk would result in a reduction
of inﬂuenza infections (21%), GP visits (20%), hospitalizations
(34%) and deaths (30%). Net savings for society of €126 million
may be expected. Per person of the Dutch population the vacci-
nation program would lead to incremental costs of—€8.00 (99%
CI -€24.00 to €8.00). If only direct medical costs were taken into
account costs to society would be €68 million. Beneﬁts in terms
of QALY gain are positive but very small due to the short time
horizon of the analysis. The most important QALY losses are
observed in those individuals that die and those that experience
stroke or heart failure. Vaccination may prevent the death of
21,615 persons. The total number of life years gained is 16,627,
resulting in 12,790 QALYs gained. CONCLUSION: A vaccina-
tion programme in which high risk individuals are vaccinated in
accordance with the current inﬂuenza prevention program is cost
saving and generates extra (quality adjusted) life years.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) infections in
infants at high risk, such as premature babies, infants with bron-
chopulmonary dysplasia (BPD), and children with congenital
heart disease (CHD). METHODS: A decision tree model was
used to estimate the cost-effectiveness of Palivizumab in high-
risk children. The data sources included published literature, the
Palivizumab clinical trials, ofﬁcial price/tariff lists and national
population statistics. The primary perspective of the study was
that of the health care purchaser (National Health Service),
which included the cost of administration and hospital care for
RSV infections. RESULTS: The use of Palivizumab results in an
ICER of £7042/QALY without discounting, which increases to
£16,720/QALY after discounting in the prophylaxis in prema-
ture infants and such with BPD. In the prophylaxis in babies 
with CHD the use of Palivizumab results in an ICER of
£2427/QALY without discounting and £6664/QALY after dis-
counting. Sensitivity analyses conﬁrmed the robustness of the
model. A scenario analysis showed that the inclusion of indirect
costs leads to further improvement in the cost-effectiveness out-
comes for Palivizumab CONCLUSION: This study showed that
Palivizumab is a cost-effective prophylaxis against RSV-
infections in infants at high risk: the use of Palivizumab results
in positive short and long-term health economic beneﬁts to the
health care purchaser.
